Stellaromics, a Boston, MA-based 3D spatial biology firm, raised $80M in Sequence B funding.
The spherical was led by Catalyst4 with participation from Stanford College Ventures.
The corporate intends to make use of the funds to help the event and commercialization of Pyxa, its 3D spatial biology platform.
Led by CEO Todd Dickinson, Stellaromics makes a speciality of 3D spatial multi-omics. Its Pyxa platform permits researchers to visualise and analyze the spatial group of cells and molecules inside thick tissue samples based mostly on its STARmap and RIBOmap applied sciences.
Key options of Pyxa embrace:
- Thick tissue evaluation
- Sub-cellular decision, multi-omic spatial profiling.
- Simplified workflow.
- Superior visualization software program.
The system is offered for order now, with an early entry program already totally subscribed and set to launch within the second half of 2025. Preliminary business shipments are estimated to start on the finish of 2025. To help researchers fascinated by producing pilot information for a Pyxa system, Stellaromics presents a devoted providers program.
FinSMEs
11/02/2025
